Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

To Assess the Safety, Reactogenicity and Immunogenicity of GSK Biologicals' Pneumococcal Conjugate Vaccine Compared to Prevenar™, Co-administered With DTPw-HBV/Hib & OPV or IPV Vaccines as a 3-dose Primary Immunization Course During the First 6 Months of Age

NCT00344318 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00344318
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00344318 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
To Assess the Safety, Reactogenicity and Immunogenicity of GSK Biologicals' Pneumococcal Conjugate Vaccine Compared to Prevenar™, Co-administered With DTPw-HBV/Hib & OPV or IPV Vaccines as a 3-dose Primary Immunization Course During the First 6 Months of Age
Lead sponsor
GlaxoSmithKline
Phase
Phase 3
Overall status
Completed
Start date
August 7, 2006
Completion date
October 17, 2007
Enrollment
806 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

infections, streptococcal